HealthModerna, Merck say mRNA treatment cuts melanoma recurrence, spread risk

US pharmaceutical giants Moderna and Merck say their vaccine reduced the risk that melanoma would return or spread. The companies describe it as the first mRNA-based cancer therapy to post positive results in a final-stage trial, raising hopes it could help patients with the deadliest form of skin cancer live longer.